- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04671849
En åpen etikett, multisenter, fase I klinisk studie for å evaluere sikkerheten, effektiviteten og farmakokinetiske egenskapene til SIM1803-1A hos pasienter med lokalt avanserte/metastatiske solide svulster med NTRK-, ROS1- eller ALK-genfusjonsmutasjoner.
This research study is done to test the safety, effectiveness and pharmacokinetic characteristics of SIM1803-1A in patients with locally advanced/metastatic solid tumors with NTRK, ROS1 or ALK gene fusion mutations. The cancer must have a change in a particular gene (NTRK1, NTRK2, NTRK3, ROS1 or ALK). SIM1803-1A is a drug that blocks the actions of these NTRK/ ROS1 /ALK genes in cancer cells and can therefore be used to treat cancer.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Shanghai, Kina
- Shanghai Chest Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adult patients with a locally advanced or metastatic solid tumor that has progressed or was nonresponsive to available therapies, are unfit for standard chemotherapy or for which no standard or available curative therapy exists;Proof of a malignancy harboring a NTRK、ROS1 or ALK fusion;Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 and a life expectancy of at least 3 month;Adequate hematologic, hepatic, and renal function;Signed informed consent form;
Exclusion Criteria:
- Any contraindications as listed in the local approved product information;Patients with unstable primary central-nervous-system tumors or metastasis, exceptions possible;Pregnancy or lactation;Clinically significant active cardiovascular disease or history of myocardial infarction;Participation in an investigational program with interventions outside of routine clinical practice;Prior treatment with other kinase inhibitor with tropomyosin receptor kinase inhibition;Active uncontrolled systemic bacterial, viral, or fungal infection;Current treatment with a strong CYP3A4 inhibitor or inducer;
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: voksne pasienter_Dose 1
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
Eksperimentell: voksne pasienter_dose 2
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
Eksperimentell: voksne pasienter_dose 3
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
Eksperimentell: voksne pasienter_dose 4
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
Eksperimentell: voksne pasienter_dose 5
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
Eksperimentell: voksne pasienter_dose 6
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
Eksperimentell: voksne pasienter_dose 7
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
Eksperimentell: voksne pasienter_dose 8
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with adverse events
Tidsramme: 5 years
|
Number of participants with adverse events |
5 years
|
|
Severity of adverse events
Tidsramme: 5 years
|
Severity of adverse events |
5 years
|
|
Maximum tolerated dose
Tidsramme: 5 years
|
Maximum tolerated dose |
5 years
|
|
Recommended dose for dose expansion
Tidsramme: 5 years
|
Recommended dose for dose expansion |
5 years
|
|
Maximum concentration of SIM1803-1A in plasma (Cmax)
Tidsramme: Predose and 0.25, 0.5, 1, 2, 4, 8,12,24and 48 hours after drug administration on Days 1 and 8 of Cycle 1(each cycle is 21 days)
|
Maximum concentration of SIM1803-1A in plasma (Cmax) |
Predose and 0.25, 0.5, 1, 2, 4, 8,12,24and 48 hours after drug administration on Days 1 and 8 of Cycle 1(each cycle is 21 days)
|
|
Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to 24 hours in fasted state (AUC(0-24)_fasted)
Tidsramme: Up to 1 day
|
Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to 24 hours in fasted state (AUC(0-24)_fasted) |
Up to 1 day
|
|
Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to infinity in fasted state (AUC_fasted)
Tidsramme: Up to 3 days
|
Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to infinity in fasted state (AUC_fasted) |
Up to 3 days
|
|
Number of participants with treatment-emergent adverse events (TEAEs)
Tidsramme: Up to 24 weeks
|
Number of participants with treatment-emergent adverse events (TEAEs) |
Up to 24 weeks
|
|
Time to maximum concentration of SIM1803-1A in plasma (Tmax)
Tidsramme: Predose and 0.25, 0.5, 1, 2, 4, 8,12,24and 48 hours after drug administration on Days 1 and 8 of Cycle 1(each cycle is 21 days)
|
Time to maximum concentration of SIM1803-1A in plasma (Tmax) |
Predose and 0.25, 0.5, 1, 2, 4, 8,12,24and 48 hours after drug administration on Days 1 and 8 of Cycle 1(each cycle is 21 days)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Response Rate (ORR)
Tidsramme: Up to 60 months
|
Overall Response Rate (ORR) |
Up to 60 months
|
|
Duration of Response (DOR)
Tidsramme: Up to 60 months
|
Duration of Response (DOR) |
Up to 60 months
|
|
progression-free survival(PFS)
Tidsramme: Up to 60 months
|
progression-free survival(PFS) |
Up to 60 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: shun lu, Ph.D, Shanghai Chest Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- SIM1803-1A-NTRK-0101
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .